Publication:
Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib

No Thumbnail Available

Date

2018-06-01T00:00:00Z

Authors

Authors

Aypar, Eda
Izzettin, FİKRET VEHBİ
Aki, Sahika Zeynep
SANCAR, MESUT
Yegin, Zeynep Arzu
Turkoz-Sucak, Gulsan

Journal Title

Journal ISSN

Volume Title

Publisher

Research Projects

Organizational Units

Journal Issue

Metrics

Search on Google Scholar

Abstract

Background Autologous hematopoietic stem cell transplantation (AHSCT) remains the standard of care for younger patients with multiple myeloma (MM). Currently, high-dose melphalan (HDM) is recommended as conditioning regimen before AHSCT. Preclinical data suggest that combining bortezomib and melphalan has synergistic effect against multiple myeloma cells. Bortezomib and HDM (Bor-HDM) combination as conditioning regimen has been investigated by many other investigators.

Description

Keywords

Citation

Aypar E., Izzettin F. V. , Aki S. Z. , SANCAR M., Yegin Z. A. , Turkoz-Sucak G., -Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib-, JOURNAL OF ONCOLOGY PHARMACY PRACTICE, cilt.24, ss.281-289, 2018

URI

http://hdl.handle.net/20.500.12645/25449

Collections

Silinecekler
Page Views

0

File Downloads

0

Sustainable Development Goals